Skip to content

Author

Long-Qin Hu

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Editorial Open access Aug 2026

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer

ROS1-targeted therapies have improved outcomes in ROS1-positive non-small cell lung cancer (NSCLC), but acquired resistance, CNS progression, and off-target toxicities remain important limitations. Zidesamtinib (Jideytro®, NVL-520) is a next-generation, brain-penetrant, tropomyosin receptor kinase (TRK)-sparing ROS1 in...

Sumi Lee, Long-Qin Hu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.